α3β4 antagonism has been said to be its secret, yet wellbutrin doesnt show any impressive reversal of addiction effects, it has been shown however to reverse benzo tolerance so i could see it being some tolerance reverser at its best, wich makes me wonder wheter some reveral of tolerance made the ibogaine researches conclude thats what gives it its magic.
Well if its not that, what is it? Epigenetic changes?
Im also sure its not the trip as many have results with treshold doses and no other trip ever cured someone of addiction, perhaps gave some insight and made them stop their addiction but thats something else.
Well if its not that, what is it? Epigenetic changes?
Wow well, reduced tolerance and craving, the plenty of anecdotes must be either placebo then or some other potent thing is going on that reverses addiction, even mental addiction and abolisement of withdrawals.Pharmacol Biochem Behav. 2003 Jun;75(3):607-18.
Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.
Maisonneuve IM, Glick SD.
Center for Neuropharmacology and Neuroscience, Albany Medical College, MC-136, 47 New Scotland Avenue, Albany, NY 12208, USA. [email protected]
Abstract
18-Methoxycoronaridine (18-MC), a novel iboga alkaloid congener that decreases drug self-administration in several animal models, may be a potential treatment for multiple forms of drug abuse. In animal models, 18-MC reduced intravenous morphine, cocaine, methamphetamine and nicotine self-administration, oral alcohol and nicotine intake, and attenuated signs of opioid withdrawal, but had no effect on responding for a nondrug reinforcer (water) and produced no apparent toxicity [Brain Res. 719 (1996) 29; NeuroReport 11 (2000) 2013; Pharmacol. Biochem. Behav. 58 (1997) 615; Psychopharmacology (Berl.) 139 (1998) 274; NeuroReport 9 (1998) 1283; Ann. N. Y. Acad. Sci. 914 (2000) 369]. Consistent with a relationship among drug sensitization, mesolimbic dopamine, and drug-seeking behavior, 18-MC also blocked the sensitized dopamine responses to morphine and cocaine in the nucleus accumbens. An extensive series of receptor studies showed that 18-MC was most potent and somewhat selective as an antagonist at alpha3beta4 nicotinic receptors. Low-dose combinations of 18-MC with other drugs known to have this same action (e.g., mecamylamine, dextromethorphan, bupropion) decreased morphine, methamphetamine, and nicotine self-administration in rats at doses that were ineffective if administered alone. Together, the data support the hypothesis that diencephalic pathways having high densities of alpha3beta4 nicotinic receptors modulate mesocorticolimbic pathways more directly involved in drug reinforcement. Antagonists of alpha3beta4 nicotinic receptors may represent a totally novel approach to treating multiple addictive disorders, and 18-MC might be the first of a new class of synthetic agents acting via this novel mechanism and having a broad spectrum of activity.
Im also sure its not the trip as many have results with treshold doses and no other trip ever cured someone of addiction, perhaps gave some insight and made them stop their addiction but thats something else.
